Literature DB >> 22019224

Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy.

Massimo Nicolò1, Daniela Zoli, Maria Musolino, Carlo Enrico Traverso.   

Abstract

PURPOSE: To determine the efficacy of half-dose photodynamic therapy (PDT) in relation to indocyanine green angiography (ICGA) and optical coherence tomography (OCT) findings for treating chronic central serous chorioretinopathy (CSC).
DESIGN: Observational case series.
METHODS: Thirty-eight eyes of 37 patients with chronic CSC and symptoms for at least 6 months were recruited. PDT was performed using half the normal dose of verteporfin. A total light energy of 50 J/cm(2) over 83 seconds was delivered to the area of choroidal hyperfluorescence as observed on ICGA. The resolution of the subretinal fluid and recurrence rates were assessed in relation to the different degrees of choroidal hyperfluorescence and the distribution of fluid in the neuroepithelium, namely subretinal fluid or posterior retinal cystoid degeneration.
RESULTS: After half-dose PDT a dry macula was obtained in 86.8% and 92.1% of the eyes at 1 month and at the last follow-up (14.2 ± 5.8 months) respectively. ICGA at baseline showed intermediate and intense hyperfluorescence in 39.4% and 60.5% of the eyes respectively. All eyes with intermediate hyperfluorescence had only subretinal fluid at OCT and a dry macula was obtained in 87% and 100% at 1 month and at the last follow-up after half-dose PDT. In the intense hyperfluorescence group, 82.6% and 17.4% of the eyes had subretinal fluid only or both subretinal fluid and posterior retinal cystoid degeneration respectively. In the intense hyperfluorescence group with subretinal fluid only, a dry macula was obtained in 89.5% and 100% of the eyes at 1 month and at the last follow-up respectively. In the intense hyperfluorescence group with both subretinal fluid and posterior retinal cystoid degeneration, a dry macula was obtained in 75% and 25% of the eyes at 1 month and at the last follow-up respectively. Overall, of the 23 eyes with intense hyperfluorescence, 20 eyes (87%) had a dry macula starting from 1 month for the entire follow-up period.
CONCLUSION: The half-dose PDT success rate in eyes with chronic CSC depends also on the distribution of fluid in the neuroepithelium. Half-dose PDT might not be effective or the recurrence rate might be high in eyes with posterior retinal cystoid degeneration. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019224     DOI: 10.1016/j.ajo.2011.08.015

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  20 in total

1.  Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence.

Authors:  Wookyung Park; Mirinae Kim; Rae Young Kim; Young-Hoon Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-07-31       Impact factor: 3.117

2.  Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes.

Authors:  S H Karakus; B Basarir; E Y Pinarci; E U Kirandi; A Demirok
Journal:  Eye (Lond)       Date:  2013-03-22       Impact factor: 3.775

3.  Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Chun-Fu Liu; Lee-Jen Chen; Shawn H Tsai; Chi-Chun Lai; Wei-Chun Chan; Wei-Chi Wu; Nan-Kai Wang; Kuan-Jen Chen; Yih-Shiou Hwang; Yen-Po Chen; Ling Yeung
Journal:  J Ocul Pharmacol Ther       Date:  2014-03-05       Impact factor: 2.671

Review 4.  [Statement and recommendation of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Situation January 2018].

Authors: 
Journal:  Ophthalmologe       Date:  2018-05       Impact factor: 1.059

Review 5.  [Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on central serous chorioretinopathy : Status 18 October 2021].

Authors: 
Journal:  Ophthalmologe       Date:  2021-12-14       Impact factor: 1.059

Review 6.  Statement of the Professional Association of Ophthalmologists in Germany (BVA), the German Society of Ophthalmology (DOG) and the German Retina Society (RG) on central serous chorioretinopathy : Status 18 October 2021.

Authors: 
Journal:  Ophthalmologie       Date:  2022-04-06

7.  Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy.

Authors:  S H Lim; W Chang; M Sagong
Journal:  Eye (Lond)       Date:  2013-03-01       Impact factor: 3.775

Review 8.  Photodynamic therapy for central serous chorioretinopathy.

Authors:  O C Erikitola; R Crosby-Nwaobi; A J Lotery; S Sivaprasad
Journal:  Eye (Lond)       Date:  2014-06-20       Impact factor: 3.775

9.  Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.

Authors:  Pedro Cuevas; Luis A Outeiriño; Carlos Azanza; Javier Angulo; Guillermo Giménez-Gallego
Journal:  Eur J Med Res       Date:  2012-07-12       Impact factor: 2.175

10.  Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.

Authors:  Myrte B Breukink; Susan M Downes; Giuseppe Querques; Elon H C van Dijk; Anneke I den Hollander; Rocio Blanco-Garavito; Jan E E Keunen; Eric H Souied; Robert E MacLaren; Carel B Hoyng; Sascha Fauser; Camiel J F Boon
Journal:  Trials       Date:  2015-09-21       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.